Sarepta Therapeutics said it will update its prescribing information for Elevidys ® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys ...
Sarepta Therapeutics has temporarily suspended use of the gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy (DMD) after a second patient taking the drug died from acute ...
Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort. Delandistrogene ...
Sarepta’s stock plunged about 38% in after-hours trading, after it closed the regular session up 1.8%. That decline would put ...
After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based Duchenne muscular dystrophy (DMD) candidate. In a phase 1/2 trial, most adverse ...
Zacks Investment Research on MSN
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
Sarepta Therapeutics, Inc. SRPT reported third-quarter 2025 adjusted loss of 13 cents per share against the Zacks Consensus ...
The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy (DMD) cell therapy, raising questions about whether the agency's new leadership may be rowing back from ...
Duchenne muscular dystrophy (DMD) follows an X-linked inheritance pattern. The condition most often affects males, while females may be carriers of the genetic change that causes it. If you have DMD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback